-
Mashup Score: 0Welcome to Gene Therapy Net - 2 year(s) ago
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy. The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of info…
Source: www.genetherapynet.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 21Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy - 2 year(s) ago
Two children died from acute liver failure after treatment with Zolgensma, a gene therapy sold by Novartis.
Source: STATCategories: Expert Picks, Latest HeadlinesTweet-
Novartis reports two children died from acute liver failure after treatment with #Zolgensma gene therapy for spinal muscle atrophy None had died in trials of the drug https://t.co/h1WYXDjqdf via @statnews
-
-
Mashup Score: 0Novartis back with bid for 'multibillion-dollar' Zolgensma expansion in older SMA patients as FDA lifts clinical hold - 3 year(s) ago
As Novartis’ gene therapy Zolgensma makes inroads in newborns diagnosed with spinal muscular atrophy, the company is looking to expand the drug’s reach to older patients with a new formulation. After a safety scare and a regulatory setback, the Swiss pharma is now back on track with that plan.
Source: FiercePharmaCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@Novartis back with bid for 'multibillion-dollar' #Zolgensma expansion in older #SMA patients as #FDA lifts clinical hold - #genetherapy https://t.co/YPseOS4j27
-
-
Mashup Score: 2Vedika Won't Make It To Her 1st Birthday Without Your Help! - 3 year(s) ago
My name is Sourabh Shinde and I am here to raise funds for my daughter Vedika Shinde who is 9 months old. She suffers from Spinal Muscular Atrophy – Type 1. There is only one cure for SMA Type-1 – Zolgensma, which is manufactured in America by Novartis. It costs nearly INR 16 crores (USD 2.1mn). Please Contribute and Share.
Source: milaap.orgCategories: Future of Medicine, Latest HeadlinesTweet-
Save Baby #Ayaansh and baby #vedika they are suffering from #spinalmuscleatrophy and need #ZOLGENSMA that costs more than 2 million dollars. Requesting @VasNarasimhan @NovartisFDN @ankiaaglko @FightsSma #ZOLGENSMA @novartis https://t.co/SNKq5WvzF8 https://t.co/Itry5QmqBn https://t.co/ZJGSWeIWBb
-
-
Mashup Score: 10Efficacy and costs of spinal muscular atrophy drugs - 3 year(s) ago
Evaluating the benefits, risks, and costs of two drugs to treat spinal muscular atrophy raises questions about the future of rare disease medicines.
Source: Science Translational MedicineCategories: Future of Medicine, Latest HeadlinesTweet-
The expensive and recently-approved drugs #zolgensma and #spinraza may offer only modest benefits for patients with #SpinalMuscularAtrophy, according to a @ScienceTM Focus examining trial data and FDA documents. https://t.co/jow0ffOyNK https://t.co/h6NIWLF7Jh
-
-
Mashup Score: 6Efficacy and costs of spinal muscular atrophy drugs - 3 year(s) ago
Evaluating the benefits, risks, and costs of two drugs to treat spinal muscular atrophy raises questions about the future of rare disease medicines.
Source: Science Translational MedicineCategories: Future of Medicine, Latest HeadlinesTweet-
The expensive and recently-approved drugs #zolgensma and #spinraza may offer only modest benefits for patients with #SpinalMuscularAtrophy, according to a @ScienceTM Focus examining trial data and FDA documents. https://t.co/jow0ffOyNK https://t.co/T4bWrAaUUC
-
-
Mashup Score: 0First oral SMA drug - 4 year(s) ago
First oral SMA drug
Source: www.nature.comCategories: Future of Medicine, Latest HeadlinesTweet-
In Brief: FDA approves the first oral drug for treating spinal muscular atrophy, developed by @PTCBio & @genentech. #Evrysdi sits alongside two other approved SMA treatments: @biogen & @ionispharma's antisense therapy #Spinraza, and @Novartis's #Zolgensma https://t.co/tiejFZzOlq
-
-
Mashup Score: 2Spinal Muscular Atrophy UK - 4 year(s) ago
SMA UK provide a range of information and support to families and health professionals as well as promoting and supporting research.
Source: smauk.org.ukCategories: Hem/Onc News and JournalsTweet-
RT @SMA_UK_: NICE confirms the HST evaluation of #Zolgensma will progress as planned, situation permitting: https://t.co/5KzeREm8Xe There’s…
-
-
Mashup Score: 0
Novartis is holding a lottery to obtain doses of Zolgensma, a gene therapy for infants with a former of spinal muscular atrophy.
Source: STATCategories: General Medicine NewsTweet-
Amid controversy and ethical debates, "winners" of the first lottery for the pricey spinal muscular atrophy drug #Zolgensma were announced this week. By @DrewQJoseph and @Pharmalot via @statnews. https://t.co/IbKwqbtqEa
-
Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma. https://t.co/JQCyx0Trgo #novartis #ZOLGENSMA